{"title":"A review on the validity of animal models for neuropsychiatric disorders: an exploration of anhedonia.","authors":"Kate M Witt, David N Harper, Bart A Ellenbroek","doi":"10.1097/FBP.0000000000000816","DOIUrl":null,"url":null,"abstract":"<p><p>Despite major advances in neuroscience, there has been limited progress in improving pharmacological treatment for neuropsychiatric disorders. Neuropsychiatric disorders are heterogeneous with variance in symptoms within disorders and partial overlap in symptoms between disorders, leading to symptoms that remain untreated. To improve treatment outcomes, neuroscience has shifted to examining the neurobiological mechanisms underlying individual components, or dysfunctions, across disorders. Anhedonia, a decreased capacity to experience pleasure from positive stimuli or rewards, is a prominent symptom associated with poor functional outcome across neuropsychiatric disorders. This article reflects on Professor Paul Willner's contributions to the field of behavioural neuroscience, specifically his promotion of validity in animal models of neuropsychiatric disorders. Research can build upon Willner's scholarship by continuing to refine and explore the validity of animal models as our understanding of neuropsychiatric disorders improves. To exemplify this, we discuss current understanding of the neurobiological basis and clinical presentation of the two domains of anhedonia: anticipation and consumption. We argue for the examination of anticipatory anhedonia and consummatory anhedonia within a single paradigm to improve understanding of these domains, aligning animal models to the clinical reality in humans.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 4","pages":"165-170"},"PeriodicalIF":1.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioural Pharmacology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1097/FBP.0000000000000816","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Despite major advances in neuroscience, there has been limited progress in improving pharmacological treatment for neuropsychiatric disorders. Neuropsychiatric disorders are heterogeneous with variance in symptoms within disorders and partial overlap in symptoms between disorders, leading to symptoms that remain untreated. To improve treatment outcomes, neuroscience has shifted to examining the neurobiological mechanisms underlying individual components, or dysfunctions, across disorders. Anhedonia, a decreased capacity to experience pleasure from positive stimuli or rewards, is a prominent symptom associated with poor functional outcome across neuropsychiatric disorders. This article reflects on Professor Paul Willner's contributions to the field of behavioural neuroscience, specifically his promotion of validity in animal models of neuropsychiatric disorders. Research can build upon Willner's scholarship by continuing to refine and explore the validity of animal models as our understanding of neuropsychiatric disorders improves. To exemplify this, we discuss current understanding of the neurobiological basis and clinical presentation of the two domains of anhedonia: anticipation and consumption. We argue for the examination of anticipatory anhedonia and consummatory anhedonia within a single paradigm to improve understanding of these domains, aligning animal models to the clinical reality in humans.
期刊介绍：
Behavioural Pharmacology accepts original full and short research reports in diverse areas ranging from ethopharmacology to the pharmacology of schedule-controlled operant behaviour, provided that their primary focus is behavioural. Suitable topics include drug, chemical and hormonal effects on behaviour, the neurochemical mechanisms under-lying behaviour, and behavioural methods for the study of drug action. Both animal and human studies are welcome; however, studies reporting neurochemical data should have a predominantly behavioural focus, and human studies should not consist exclusively of clinical trials or case reports. Preference is given to studies that demonstrate and develop the potential of behavioural methods, and to papers reporting findings of direct relevance to clinical problems. Papers making a significant theoretical contribution are particularly welcome and, where possible and merited, space is made available for authors to explore fully the theoretical implications of their findings. Reviews of an area of the literature or at an appropriate stage in the development of an author’s own work are welcome. Commentaries in areas of current interest are also considered for publication, as are Reviews and Commentaries in areas outside behavioural pharmacology, but of importance and interest to behavioural pharmacologists. Behavioural Pharmacology publishes frequent Special Issues on current hot topics. The editors welcome correspondence about whether a paper in preparation might be suitable for inclusion in a Special Issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
